| ²é¿´: 711 | »Ø¸´: 1 | |||
ÐÇÐǵãÅÚгæ (Ö°Òµ×÷¼Ò)
|
[½»Á÷]
FDAÅú×¼µÄÒ»ÖÖÃÀÈÝÒ© ÒÑÓÐ1È˲ÎÓë
|
|
The prostaglandin analogue bimatoprost (Latisse® , which has been marketed byAllergan since 2001 for the treatment of glaucoma, was launched last year for an entirely new indication: the treatment of hypotrichosis of eyelashes. Patients with this medical aesthetic condition have inadequate or not enough eyelashes. The new indication was discovered serendipitously, upon the observation that patients using bimatoprost to treat open-angle glaucoma experienced eyelash growth as a side effect. In subsequent clinical studies, Allergan demonstrated that the once-daily application of bimatoprost led to improved eyelash length, thickness and darkness, together with a favorable safety profile. |
» ²ÂÄãϲ»¶
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ157È˻ظ´
·Ö×Ó¶Ô½ÓÏà¹Ø¾Ñé·ÖÏí
ÒѾÓÐ0È˻ظ´
·Ö×Ó¶Ô½ÓÏà¹Ø¾Ñé·ÖÏí
ÒѾÓÐ0È˻ظ´
ÇóÖúÖйúÒ©µä1995Äê°æ¡¢¶þ²¿
ÒѾÓÐ0È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
ÇóÖúhttps://www.pnas.org/doi/10.1073/pnas.2535777123 È«ÎÄ
ÒѾÓÐ0È˻ظ´
2026ÉúÎïÒ½Ò©²úÒµ·¢Õ¹´ó»á
ÒѾÓÐ0È˻ظ´
¹úÇàÖÐÁË
ÒѾÓÐ23È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
2014ÄêÉϰëÄêÃÀ¹úFDAÅú×¼Ò©Îï¼ò½é
ÒѾÓÐ14È˻ظ´
Olodaterol Respimat2014Äê7ÔÂFDAÅú×¼µÄÖÎÁƷβ¡Ò©Îï
ÒѾÓÐ13È˻ظ´
FDAÅú×¼»ÒÖ¸¼×Ò© 2012.10ÏòFDAÉ걨NDA
ÒѾÓÐ10È˻ظ´
2014ÄêµÚÒ»¼¾¶ÈFDAÅú×¼µÄ9¸öÐÂÒ©
ÒѾÓÐ15È˻ظ´
2013ÄêÃÀ¹úFDAÅú×¼´´ÐÂÒ©¸Å¿ö
ÒѾÓÐ17È˻ظ´
FDAÅú×¼ÐÂÒ©HemangeolÉÏÊÐ
ÒѾÓÐ7È˻ظ´
2013Äê FDA Åú×¼µÄÐÂÒ© £¨Nature Review )
ÒѾÓÐ283È˻ظ´
ÇëÎÊÈçºÎ²éѯ±»FDAÅú×¼ÓÃÓÚÈ˵IJÄÁÏ£¿
ÒѾÓÐ6È˻ظ´
2012Äê3ÔÂFDAÅú×¼ÐÂÒ©
ÒѾÓÐ8È˻ظ´
Ëû·úǰÁÐËØ»ñµÃFDAÅú×¼ÓÃÓÚÖÎÁÆÇà¹âÑÛ»òÑÛ¸ßѹ
ÒѾÓÐ6È˻ظ´
Ivacaftor-2012Äê1ÔÂFDAÅú×¼µÄÖÎÁÆÄÒÐÔÏËά»¯µÄÒ©Îï
ÒѾÓÐ21È˻ظ´
2011 FDAÅú×¼µÄзÖ×ÓʵÌåÒ©Îï
ÒѾÓÐ12È˻ظ´
ÔõÑù´ÓÃÀ¹úFDAÍøÕ¾ÉϲéÕÒ¼°ÏÂÔØÒ©Æ·ËµÃ÷Ê飿
ÒѾÓÐ11È˻ظ´
2011ÄêFDAÅú׼вúÆ·
ÒѾÓÐ6È˻ظ´
FDAÅú×¼»ÔÈðµÄXALKORI(Crizotinib)
ÒѾÓÐ5È˻ظ´
¡¾×ªÌû¡¿2010ÄêFDAÅú×¼ÄÄЩÐÂÒ©?
ÒѾÓÐ5È˻ظ´

trsdfae
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 27.8
- ºì»¨: 3
- Ìû×Ó: 230
- ÔÚÏß: 9.4Сʱ
- ³æºÅ: 3299390
- ×¢²á: 2014-06-30
2Â¥2014-12-04 08:43:05









, which has been marketed by
»Ø¸´´ËÂ¥
ͶƱ: